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Abstract Chronic myeloid leukemia (CML) is a type of he-
matological malignancy that is characterized by the generation
of Philadelphia chromosome encoding BCR/ABL
oncoprotein. Tyrosine kinase inhibitors (TKIs), imatinib,
nilotinib, and dasatinib, are used for the frontline therapy of
CML. Development of resistance against these TKIs in the
patients bearing T315I mutation is a major obstacle in CML
therapy. Ponatinib, the third-generation TKI, is novel drug that
is effective even in CML patients with T315I mutation. The
exact mechanism of ponatinib in CML has been still un-
known. In this study, we aimed to determine the potential
mechanisms and structural metabolic changes activated by
ponatinib treatment in imatinib-sensitive K562 human CML
cell lines and 3 μM-imatinib-resistant K562/IMA3 CML cell
lines generated at our lab. Apoptotic and antiproliferative ef-
fects of ponatinib on imatinib-sensitive and 3 μM-imatinib-
resistant K562/IMA3 CML cells were determined by prolifer-
ation and apoptosis assays. Additionally, the effects of
ponatinib on macromolecules and lipid profiles were also an-
alyzed using Fourier transform infrared spectroscopy (FTIR).
Our results revealed that ponatinib inhibited cell proliferation
and induced apoptosis as determined by loss of mitochondrial
membrane potential, increased caspase-3 enzyme activity, and
transfer of phosphatidylserine to the plasmamembrane in both
K562 and K562/IMA-3 cells. Furthermore, cell cycle analyses
revealed that ponatinib arrested K562 and K562/IMA-3 cells
at G1 phase. Moreover, ponatinib treatment created a more
ordered nucleic acid structure in the resistant cells. Although
the lipid to protein ratio increased in imatinib-sensitive K562
cells with a little decrease in the K562/IMA-3 cells, ponatinib
treatment indicated significant changes in the lipid composi-
tion such as a significant increase in the cellular cholesterol
amounts much more in the K562/IMA-3 cells than the sensi-
tive counterparts. Unsaturation in lipids was higher in the
resistant cells; however, increases in lipids without phosphate
and the number of acyl chains were much higher in the K562
cells. Taken together, all these results showed powerful anti-
proliferative and apoptotic effects of ponatinib in both
imatinib-sensitive and imatinib-resistant CML cells in a
dose-dependent manner, and hence, the use of ponatinib for
the treatment of TKI-resistant CML patients may be an effec-
tive treatment approach in the clinic. More importantly, these
results showed that FTIR spectroscopy can detect drug-
induced physiological changes in cancer drug resistance.
Keywords Ponatinib . Chronic myeloid leukemia (CML) .
Multidrug resistance (MDR) . Imatinib . Fourier transform
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Introduction
Chronic myeloid leukemia (CML), a type of hematological
malignancy, is characterized by the reciprocal translocation
between the breakpoint cluster region (BCR) gene on chro-
mosome 22 and the Abelson murine leukemia virus (ABL)
gene on chromosome 9, t(9;22)(q34;q11). This translocation
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results in the formation of Philadelphia (Ph) chromosome cod-
ing for BCR/ABL fusion protein having constitutively active
tyrosine kinase activity [1]. BCR/ABL can phosphorylate and
activate many signaling molecules inducing cell proliferation
and survival. For this reason, tyrosine kinase inhibitors (TKIs)
are the main drugs used in CML therapy [2]. In the clinic,
tyrosine kinase inhibitors are used as frontline therapy due to
their efficiency in acquiring early optimum responses in CML
[3]. However, resistance can be observed in many cases via
several ways [4]. T315I mutation, one of the frequently en-
countered mutations, causes an important obstacle in CML
therapy. This mutation results in the switch of the amino acid
threonine at position 315 into isoleucine [5]. Patients bearing
T315I mutation are resistant to imatinib, nilotinib, and
dasatinib [6].
The third-generation TKI, ponatinib, is an FDA-
approved drug that is effective even in CML patients
with T315I mutation [7]. This isoleucine residue removes
the hydrogen bond and prevents the TKIs to bind to the
ATP-binding pocket of BCR/ABL. Since ponatinib bears
a particular carbon–carbon triple bond preventing the ste-
ric hindrance as a result of T315I mutation, it can bind
and inhibit BCR/ABL kinase. In addition to BCR/ABL
kinase, ponatinib can also inhibit Src kinase, KIT, FLT3,
PDGFR, VEGFR, and FGFR [8].
Fourier transform infrared spectroscopy allows for
rapid, sensitive, and non-destructive method analysis of
samples in any physical state [9, 10]. It monitors molec-
ular changes in the analysis of biological systems at the
functional group level. The digital spectral data can be
analyzed with many different manipulations. These ma-
nipulations yield both qualitative and quantitative infor-
mation. In obtaining spectral data, shifts in peak posi-
tions and changes in bandwidths and band intensities
are used to obtain structural and functional information
and also changes in cellular components such as lipids,
proteins, carbohydrates, and nucleic acids in the systems
analyzed [9, 11]. The changes in the studied tissue or
cells indicate specific biological differentiation processes
such as disease progression.
In this study, we aimed to examine apoptotic and
antiproliferative effects of ponatinib, and also its effects
on macromolecules and lipid profiles in imatinib-
sensitive and imatinib-resistant K562/IMA-3 CML cells.
For this purpose, imatinib resistance was induced in
K562 cells. Although resistance-dependent macromolec-
ular changes in various types of cancers against differ-
ent anticancer drugs including nilotinib have been inves-
tigated using Fourier transform infrared spectroscopy
(FTIR) technique [12–14], this is the first detailed study
investigating the changes between imatinib-sensitive and
imatinib-resistant K562/IMA-3 cells in terms of bio-
chemical variations.
Materials and methods
Cell lines and chemicals K562 human chronic myeloid leu-
kemia cells were obtained from German Collection of Mi-
croorganisms and Cell Cultures (Germany). Ponatinib was
obtained from Selleck Chem Chemicals (USA), and stock
solution (162 mM) was dissolved in dimethylsulfoxide
(DMSO). Imatinib mesylate was obtained from Novartis
(Gleevec, USA).
Culture conditions K562 and K562/IMA-3 human chronic
myeloid leukemia cells were maintained in RPMI-1640
growth medium containing 10 % fetal bovine serum and
1 % penicillin–streptomycin (Invitrogen, Paisley, UK) at
37 °C in 5 % CO2. K562/IMA-3 cells were generated in our
lab.
Measurement of cell proliferation byMTTassay Cytotoxic
effects and IC50 values (drug concentrations inhibiting cell
proliferation by 50 %) of ponatinib on K562 and K562/
IMA-3 cells were determined by MTT cell proliferation assay
as explained [15].
Examining the loss of mitochondrial membrane potential
Apoptotic effects of ponatinib on K562 and K562/IMA-3
CML cells were examined by using a JC-1 mitochondrial
membrane potential detection kit (Cell Technology, USA) as
explained [16]. This kit uses JC-1, a unique cationic dye, to
signal the loss of theMMP. JC-1 accumulates in themitochon-
dria and stains red in non-apoptotic cells while JC-1 remains
in the cytoplasm as a monomer that stains green under fluo-
rescent light in apoptotic cells.
Examining the changes in caspase-3 enzyme activity
Changes in caspase-3 enzyme activity of the cells were exam-
ined by caspase-3 colorimetric assay kit (BioVision Research
Products, USA). This assay is based on the spectrophotomet-
ric detection of the chromophore p-nitroanilide (pNA) after
cleavage from the labeled substrate DEVD-pNA that can be
recognized by caspases as explained [16].
Examining the apoptotic cell population by annexin-V
FITC staining In order to confirm the results of caspase-3
enzyme activity and mitochondrial membrane potential analy-
ses, we also determined the translocation of phosphatidylserine
from the inner membrane to the outer cell membrane by using
an annexin-V FITC staining kit (BioVision Research Products,
CA) as explained [17].
Cell cycle analysis Effects of ponatinib on cell cycle were
also assessed by cell cycle analysis in K562 and K562/IMA-
3 CML cells. Cell cycle analysis is based on the determination
of amounts of dsDNA by using propidium iodide, a DNA-
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binding dye, via flow cytometry. When the data acquired from
the flow cytometry are analyzed, cell cycle phases and the
amounts of fragmented DNA of the cells can be determined
as explained [16].
Sample preparation for FTIR spectroscopy In order to pre-
pare the cells for FTIR spectroscopy, 5×106 cells were seeded
into 75 cm2 culture flasks with 20 ml of growth medium, and
the cells were treated with IC50 values of ponatinib for each
cell line (1.72 nM for K562 cells and 28.5 nM for K562/IMA-
3 cells) for 72 h. After the incubation period, the cells were
collected by centrifugation at 800 rpm for 5 min. Supernatants
were removed, and the pellets were homogenized with PBS to
be 5×106 cells/ml. The collected cells were lyophilized in a
freeze drier (Labconco, FreeZone 18-l freeze dry system)
overnight to remove water. The cell powder was mixed with
dried potassium bromide (KBr) (Sigma-Aldrich, USA) in a
mortar (at a ratio of 1:100). The mixture was then pressurized
to 100 kg/cm2 (1200 psi) for 5 min. All the cell growth, cell
collection, and FTIR experiment for the imatinib-sensitive and
imatinib-resistant K562 cells were carried out on the same
day.
Lipid extraction In order to extract lipids from the cells, 10×
106 cells were seeded into 75 cm2 culture flasks with 20 ml of
growth medium, and the cells were treated with IC50 values of
ponatinib for each cell line (1.72 nM for K562 cells and
28.5 nM for K562/IMA-3 cells) for 72 h. After the incubation
period, the cells were collected by centrifugation at 800 rpm
for 5 min. Supernatants were removed, and the pellets were
homogenized with PBS and then again centrifuged at 800 rpm
for 5 min. Afterwards, the supernatant was removed and the
cell pellet was homogenized with 2 ml of extraction mixture
including chloroform/methanol (2:1, v/v) via vortexing. Then,
the mixture was incubated for 20 min at room temperature.
After the incubation period, 500 μl 37 % HCl was added onto
the mixture, and after vortexing to homogenize the mixture, it
was centrifuged at 500×g for 10 min. At the end of the cen-
trifugation, the lower layer including chloroform was collect-
ed for the analysis [18].
FTIR spectrum accumulation and data processing A
PerkinElmer spectrometer equipped with MIR TGS detector
was used for recording the spectra (Spectrum 100 Instrument,
PerkinElmer Inc., Norwalk, CT, USA). FTIR spectra of the
samples were recorded between 4000 and 450 cm−1. Interfer-
ograms were taken for 20 scans at 4 cm−1 resolution and then
averaged. The background spectrum was automatically
subtracted from the spectra of the samples. All data manipu-
lations were carried out in Spectrum 100 software
(PerkinElmer). From each sample, at least three different
scans, which gave identical spectra, were performed. These
replicates (n=5 for both the sensitive and resistant cells) were
averaged, and the averaged spectra for each sample were then
used for further data manipulation and statistical analysis.
For the visual demonstration of the spectral data, the spec-
tra were interactively baselined from two arbitrarily selected
points. Then the spectra were normalized in specific regions
for visual comparison of ponatinib-treated imatinib-sensitive
and imatinib-resistant samples [19].
Since water was removed from the samples in the sample
preparation steps using lyophilization procedures, therefore
water’s contribution to the amide bands was negligible in this
study.
Statistical analysis The differences between the ponatinib-
treated imatinib-sensitive and imatinib-resistant groups were
compared using the Mann–Whitney U test with the Matlab
R2011a program. The statistical results are expressed as
means±standard deviation. P<0.05 was considered statisti-
cally significant.
Results
Ponatinib showed dose-dependent cytotoxicity on K562
and K562/IMA-3 cells To assess antiproliferative effects of
ponatinib on K562 and K562/IMA-3 cells, the cells were
treated with increasing concentrations of ponatinib (0.5 to
100 nM) for 72 h and MTT cell proliferation assay was con-
ducted. The results showed that there were dose-dependent
decreases in cell proliferation in response to ponatinib as com-
pared to untreated controls. IC50 values were calculated from
cell proliferation plots and were found to be 1.72 and 28.5 nM,
in K562 and K562/IMA-3 cells, respectively (Fig. 1).
Ponatinib-induced loss of MMP in K562 and K562/IMA-3
cells in a dose-dependent manner In order to examine the
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Fig. 1 Cytotoxic effects of ponatinib in K562 and K562/IMA-3 cells
treated with increasing concentrations of ponatinib (0.5–100 nM) for
72 h at 37 °C. P<0.05 was considered to be significant. The error bars
represent the standard deviations, and when not seen, they are smaller
than the thickness of the lines on the graphs
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apoptotic effects of ponatinib onK562 and K562/IMA-3 cells,
we treated the cells with increasing concentrations of
ponatinib (10 to 100 nM) for 72 h and analyzed the changes
in loss of MMP. The results showed that the increasing con-
centrations of ponatinib significantly increased the MMP.
There were 1.3- to 3.6-fold and 1- to 6.6-fold increases in loss
of MMP in K562 and K562/IMA-3 cells in response to
ponatinib, respectively, as compared to untreated controls
(Fig. 2).
Ponatinib treatment increased caspase-3 enzyme activity
in K562 and K562/IMA-3 cells in a dose-dependent man-
nerK562 and K562/IMA-3 cells were treated with increasing
concentrations of ponatinib (10 to 100 nM) for 72 h, and
changes in caspase-3 enzyme activity were examined. The
results demonstrated that increasing concentrations (10 to
100 nM) of ponatinib increased caspase-3 enzyme activity
from 1.8- to 2.4-fold and from 1- to 1.5-fold in K562 and
K562/IMA-3 cells, respectively, as compared to untreated
controls (Fig. 3).
Ponatinib treatment increased apoptotic cell population of
K562 and K562/IMA-3 cells Apoptotic effects of ponatinib
were confirmed by examining the apoptotic cell population
with an annexin-V FITC assay via flow cytometer. The results
showed that the increasing concentrations of ponatinib signif-
icantly increased the apoptotic cell populations. Apoptotic cell
population increased from approximately 2- to 8.5-fold in
K562 cells in response to (10 to 100 nM) ponatinib while there
were 7.8- and 9.7-fold increases in K562/IMA-3 cells exposed
to 50 and 100 nM ponatinib, respectively (Figs. 4 and 5).
The effects of ponatinib on cell cycle progression of K562
and K562/IMA-3 cells Cytostatic effects of ponatinib on
K562 and K562/IMA-3 cells were analyzed via flow
cytometer. Cell cycle analyses revealed that ponatinib treat-
ment resulted in cell cycle arrest at G1 phase on K562 and
K562/IMA-3 cells (Fig. 6a, b).
The effects of ponatinib on macromolecules in K562 and
K562/IMA-3 cellsWe previously reported our FTIR spectro-
scopic comparison of imatinib-sensitive and imatinib-resistant
K562 cells [20]. However, due to the changes induced by the
resistance formation, the response of the drug-sensitive and
drug-resistant cells to a second drug was not studied in terms
of FTIR spectroscopic means. Therefore, in this study, the
structural–metabolic changes induced by ponatinib as the
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Fig. 2 Effects of ponatinib on changes inMMP in K562 andK562/IMA-
3 cells treated with increasing concentrations of ponatinib (10–100 nM)
for 72 h at 37 °C. P<0.05was considered to be significant. The error bars
represent the standard deviations, and when not seen, they are smaller
than the thickness of the lines on the graphs
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Fig. 3 Effects of ponatinib on changes in caspase-3 enzyme activity in
K562 and K562/IMA-3 cells treated with increasing concentrations of
ponatinib (10–100 nM) for 72 h at 37 °C. P<0.05 was considered to be
significant. The error bars represent the standard deviations, and when
not seen, they are smaller than the thickness of the lines on the graphs
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Fig. 4 Effects of ponatinib on apoptotic cell populations in K562 and
K562/IMA-3 cells treated with increasing concentrations of ponatinib
(10–100 nM) for 72 h at 37 °C. P<0.05 was considered to be significant.
The error bars represent the standard deviations, and when not seen, they
are smaller than the thickness of the lines on the graphs
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Fig. 5 Quadrant analysis of effects of ponatinib on apoptotic cell populations in K562 and K562/IMA-3 cells treated with increasing concentrations of
ponatinib (10–100 nM) for 72 h at 37 °C
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second drug on imatinib-sensitive and imatinib-resistant K562
cells were compared using FTIR.
In Fig. 7, the average FTIR spectra of control K562 cells in
the 3840–940 cm−1 spectral regions were shown. Assign-
ments of the major bands in Fig. 7 are presented in Table 1.
The spectra were analyzed for the following regions: 2800–
3700 cm−1 for the analysis of proteins and lipids, and 1590–
1774 cm−1 for the analysis of proteins and lipids, 944–
1352 cm−1 for the analysis of the fingerprint region. In the
figures below, all the spectra presented were normalized with
respect to specific selected bands and were used only for il-
lustrative purposes. The measurement of the spectral parame-
ters was considered separately for both control and treated
groups of the imatinib-sensitive and imatinib-resistant K562
cells.
2800–3700 cm−1 region The average FTIR spectra of the
sensitive and K562/IMA-3 cells in the 2800–3700 cm−1 spec-
tral region are shown in Fig. 8a. Amide A and amide B bands
are found in this spectral region. They both have contributions
from mainly the N–H stretching of proteins with a small con-
tribution from the O–H stretching of polysaccharides and in-
termolecular H bonding and contributions fromC–N andN–H
stretching of proteins, respectively [21].
Ponatinib treatment induced remarkable changes in the
bandwidth, intensity, and frequency value of the FTIR
bands in this region as seen from Fig. 8 on the both
imatinib-sensitive and imatinib-resistant K562 cells. Com-
parisons of the band intensities of some infrared bands of
imatinib-sensitive and imatinib-resistant K562 cells are
shown in Fig. 9. In Fig. 8a, the imatinib-sensitive cells
were not found to change too much in the amide A band
which is located around 3300 cm−1 and the amide B band
which is located around 3060 cm−1. However, there was a
considerable decrease in the intensities of the both bands
after ponatinib administration.
When normalized with the intensity of the amide I band,
the Amide A/amide I intensity increases 7.72 % for imatinib-
sensitive cells but a 9.68 % reduction was observed for
imatinib-resistant cells as seen in Fig. 8a, b.
The C–H stretching vibrations of aliphatic compounds are
populated between 2996 and 2840 cm−1 as shown in Fig. 10.
When normalized to the band at 2925 cm−1, the intensity of
the CH3 asymmetric band at 2960 cm
−1 and CH3 symmetric
stretch band at 2873 cm−1 decreased for the imatinib-resistant
K562 cells, whereas no significant changes were observed for
the imatinib-sensitive K562 cells upon ponatinib administra-
tion as seen in Fig. 10a, b.
The intensity ratio of the bands at 2874 and 2852 cm−1
decreased by 0.08076 % in the imatinib-sensitive and
2.0886 % for the imatinib-resistant K562 cells (P<0.0001).
In addition, the intensity ratio of 2852 and 2926 cm−1 de-
creased by 1.1032 % in the imatinib-sensitive and increased
by 0.8014 % in the imatinib-resistant K562 cells (P<0.0001).
The frequency of the CH3 asymmetric stretch band around
2959 cm−1 band shifted from 2960.1417±0.5045 to
2959.6036±0.0914 cm−1 in the imatinib-sensitive K562 cells.
Similarly, the same band downshifted from 2959.7196±
0.1192 to 2959.4966±0.1456 cm−1 in the imatinib-resistant
K562 cells (P<0.005).
1590–1774 cm−1 region The average FTIR spectra of the
imatinib-sensitive and imatinib-resistant K562 cells upon
ponatinib introduction in the 1774–1590 cm−1 spectral region
is shown in Fig. 11a, b. The band centered at 1740 cm−1 is
mainly assigned to the C=O ester stretching vibration of tri-
glycerides and cholesterol esters [9, 22, 23]. As seen in the
figure, the intensity of the C=O ester stretching vibration did
not show significant changes for the imatinib-resistant K562
cell, but for the imatinib-sensitive K562 cells, 3.7462 % de-
crease was observed. The frequency of the band shows signif-
icant changes in the imatinib-resistant K562 cells indicating
3600 3200 2800 2400 2000 1800 1600 1400 1200 1000
Wavenumber (cm-1)
)yrartibra(
ecnabrosb
A
1
2 3
4
5 6
7 8
9 10 11 12
13
Fig. 7 The general FTIR
spectrum of K562 cells in the
3340–940 cm−1 region
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significant changes in the composition of the neutral lipids
found in the imatinib-resistant K562 cells. The band at
1659 cm−1 is amide I of proteins. Its shape is indicative of
protein secondary structures. Since the shapes of the bands did
not show significant changes upon ponatinib introduction, it
can be said that ponatinib did not introduce significantly dif-
ferent changes in the both imatinib-sensitive and imatinib-
resistant K562 cells. A similar behavior was observed when
the Amide I/amide II ratios were considered. This ratio in-
creased by only 0.6429 % for the imatinib-sensitive K562
cells and increased by 0.8851 % for the imatinib-resistant
K562 cells upon ponatinib administration.
944–1352 cm−1 (fingerprint) region The FTIR spectra in the
944–1352 cm−1 region is named fingerprint region. The bands
in this spectral region showed significant changes upon
ponatinib administration as shown in Fig. 11a, b. The band
at 1452 cm−1 is attributed to CH2 bending vibration of lipids
[24, 25] as seen in Fig. 11a. The changes in the intensity of the
shoulder around 1465 cm−1 are more pronounced in the
imatinib-resistant K562 cells upon ponatinib introduction.
The bands at 1239 and 1086 cm−1 are of nucleic acids and
attributed to PO2
− asymmetric and symmetric stretch [26, 27].
The intensity of the band at 1239 cm−1 increased significantly
in the imatinib-resistant cells. In addition, the changes in the
intensities of these bands were seen to be more drastic in the
imatinib-resistant cells in Fig. 12b. A shoulder around the
band at 1040 cm−1 indicates significant changes in the nucleic
acids of imatinib-resistant K562 cells. The band at 1155 cm−1
is attributed to C–O stretching of glycogen [28]. A notable
increase in the intensity of this band was observed in both
types of cells but in the imatinib-resistant cells being more
pronounced as seen in Fig. 12b. The band at 970 cm−1 is
assigned to C–N+–C stretch of nucleic acids [29].
Table 1 The general FTIR band assignments of K562 cells
Band number Wavenumbers (cm−1) Definition of the spectral assignment
1 3294 Amide A: mainly N–H stretching of proteins with the little contribution from O–H stretching of
polysaccharides and intermolecular bonding
2 2960 CH3 asymmetric stretch: mainly lipids, with the little contribution from proteins and carbohydrates
3 2925 CH2 asymmetric stretch: mainly lipids and the little contribution from proteins and carbohydrates
4 2873 CH3 symmetric stretch: mainly proteins, with the little contribution from lipids and carbohydrates
5 2854 CH2 symmetric stretch: mainly lipids, with the little contribution from proteins, nucleic acids, and
carbohydrates
6 1743 Ester C=O stretch: triglycerides and cholesterol esters
7 1655 Amide I: proteins, mainly C=O stretch
8 1545 Amide II: proteins, mainly N–H bend and C–N stretch
9 1453 CH2 bending: mainly lipids, with the little contribution from proteins, CH3 asymmetric bending:
methyl groups of proteins
10 1399 COO– symmetric stretch: mainly lipids with the little contribution from proteins; CH3 symmetric
bending: methyl groups of proteins
11 1240 PO2
− asymmetric stretch: mainly nucleic acids with the little contribution from phospholipids
12 1086 PO2
− symmetric stretch: nucleic acids and phospholipids; C–O stretch: glycogen
13 970 C–N+–C stretch: nucleic acids
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Fig. 8 The FTIR spectra of the ponatinib-treated (dotted line) and control
(continuous line) imatinib-sensitive (a) and imatinib-resistant (b) K562
cells between 3700 and 2800 cm−1 (the spectra were normalized with
respect to the CH2 asymmetric stretch band, which is observed at
2925 cm−1)
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In the analysis of the bands in this region, the intensity ratio
of the 1030 cm−1 and 1080 cm−1 bands decreased by 4.9416 %
in the sensitive K562 cells but increased by 19.6072 % in the
resistant K562 cells (P<0.005). Similarly, in the same figure,
the intensity ratio of 1030 and 2926 cm−1 bands decreased by
15.2156 % (P<0.005) and increased by 25.4531 % in the re-
sistant cells; 1080 cm−1 and amide II bands decreased by
4.46 % in the sensitive cells whereas they increased by
1.9668 % in the resistant cells (P<0.005). A decent increase
(6.4279 %) in the sensitive cells and a considerable decrease
(25.4922 %) in the intensity ratio of the 1121 and 1020 cm−1
bands were observed in the imatinib-resistant cells (P<0.005).
For a more detailed study in this region, a secondary
derivative analysis was carried out. For this purpose, the
second derivative of each baseline corrected sample was
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Fig. 11 The FTIR spectra of ponatinib-treated (dotted line) and control
(solid line) imatinib-sensitive (a) and imatinib-resistant (b) K562 cells
between 1774 and 1590 cm−1 (the spectra were normalized with respect
to the amide I band, which is observed at 1659 cm−1)
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taken and their peak minimum was recorded. The aver-
age second derivative spectra for the ponatinib-treated
and untreated K562 imatinib-sensitive and imatinib-
resistant cells are represented in Fig. 13a, b. The inten-
sity ratio of the second derivative spectra for 1069 cm−1
(disordering structure) and 1053 cm−1 (ordering struc-
ture) was studied as the measure of nucleic acid struc-
tural order [30]. Our results indicated that as ponatinib
was applied, the sensitive cells did not experience a
change in their order status; however, the same treat-
ment created a more ordered nucleic acid structure in
the resistant cells. In addition, it was clear that resistant
cells had more ordered nucleic acid structures when
compared with the sensitive counterparts.
FTIR spectroscopic comparison on the lipid profiles of
ponatinib treatment The possible changes in the lipid
metabolism of K562 cells were tested using the FTIR
method on the lipid extracts of the cells. The FTIR
spectra of the lipid extracts of the imatinib-sensitive
and imatinib-resistant K562 cells indicated several im-
portant changes as can be seen in Fig. 14a, b. The
assignments of the major peaks in the lipid extract spec-
tra are given in Table 2.
The FTIR spectra of the sensitive and resistant cells
were investigated in two different spectral regions. In
the first region, the spectra were investigated between
3134 and 2800 cm−1 as represented in Fig. 14a, b. In
the second part, the region between 1800 and 630 cm−1
was investigated as shown in Fig. 15a, b. It is seen in
Fig. 16a, b that the cholesterol peak at around 698 cm−1
increased with ponatinib treatment in the imatinib-
resistant K562 cells much higher than that for
imatinib-sensitive K562 cells. In general, it is seen that
ponatinib treatment affects imatinib-resistant cells more
dramatically than imatinib-sensitive K562 cells. A new
band arose as seen in Fig. 15b at 3083, 3061, and
3026 cm−1. The intensity changes in the lipid extracts
(Fig. 17) of the sensitive and resistant cells observed
upon ponatinib treatment were used to calculate the
physical variables as presented in Table 3. In all cases,
these variables were observed to increase after ponatinib
treatment except for lipids without phosphate for
imatinib-resistant K562 cells. In addition, the difference
in the changes in the number of acyl chains for both
types of cells was again significant. However, there have
been significant changes in the amounts of these
changes.
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Fig. 12 The FTIR spectra of ponatinib-treated (dotted line) and control
(solid line) imatinib-sensitive (a) and imatinib-resistant (b) K562 cells
between 1352 and 944 cm−1 (the spectra were normalized with respect
to the amide I band, which is observed at 1080 cm−1)
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Fig. 13 The average second derivative spectra of imatinib-sensitive and
imatinib-resistant (the uppermost spectra) K562 cells for ponatinib-
treated (dotted line) and untreated (solid line) groups
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Discussion
Since BCR/ABL oncoprotein exists broadly in CML patients
and has constitutive tyrosine kinase activity affecting down-
stream pathways related to cell proliferation and survival, it
has been considered as an open target for therapeutic applica-
tions. Therefore, tyrosine kinase inhibitors have been devel-
oped for the therapy [31]. Since 2001, imatinib has been used
as Bgold standard therapy^ due to its strong cytotoxic effects
on CML cells [32]. Development of resistance against imatin-
ib as well as the second-generation TKIs, nilotinib and
dasatinib, is a major obstacle for CML therapy. The most
aggressive cause of this resistance is T315I mutation. Imatin-
ib, nilotinib, and dasatinib, which are frontline therapeutics for
CML, cannot be effective for CML patients bearing T315I
mutation. Ponatinib, one of the third-generation TKIs, is
known to be effective in CML patients even bearing T315I
mutation because of its capability to bind to BCR/ABL kinase.
In a phase I clinical trial, it has been reported that ponatinib
treatment of CML patients with T315I mutation results in
hematological response in all of the patients, complete cyto-
genetic response (CCyR) in 75 % of the patients, and also
major molecular response (MMR) in 67 % of the patients
[33]. A phase II international clinical study, Ponatinib Ph+
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Fig. 14 The general FTIR
spectrum of the lipid extracts of
ponatinib-treated (dotted line) and
control (continuous line)
imatinib-sensitive (a) and
imatinib-resistant (b) K562 cells
in the 4000–650 cm−1 region
Table 2 The band assignments of the lipid extracts of K562 cells
Wavenumbers (cm−1) Definition of the spectral assignment
3002 Olefinic =CH stretching
2960 CH3 asymmetric stretching
2925 CH2 asymmetric stretching
2854 CH2 symmetric stretching
1743 Ester C=O stretching
1542 N–H bending
1216 PO2
− stretching
698 Cholesterol
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ALL and CML Evaluation (PACE), has reported that CCyR is
seen in 46 % of CML patients with T315I mutation [34].
Despite the daily increase of studies on the effects of ponatinib
on CML cells, the exact mechanism of action on CML is still
unknown.
In this study, we observed cytotoxic, cytostatic, and apo-
ptotic effects of ponatinib on both imatinib-sensitive and
imatinib-resistant CML cells. Moreover, we also investigated
the effects of ponatinib on changes in the macromolecular
structures of imatinib-sensitive and imatinib-resistant CML
cells. Our results showed that ponatinib is effective on
K562/IMA-3 cells as well as imatinib-sensitive K562 cells,
and inhibits cell proliferation (Fig. 1) via triggering apoptosis
(Figs. 2, 3, 4, and 5) and cell cycle arrest at G1 phase (Fig. 6).
Previously, apoptotic effects of ponatinib were reported in
several types of resistant CML cell lines [35], but in this study,
we also showed the effects of ponatinib on cell cycle and
macromolecular changes in both K562 and K562/IMA-3
cells. Moreover, FTIR results showed that the band around
the 3300 cm−1 band (amide A) is considered to be due to
proteins and polysaccharides. The reduction in the intensity
ratios of Amide A to Amide I in the imatinib-resistant cells
upon ponatinib treatment can be due to the reduced contribu-
tion of glycogen. However, a significant increase was ob-
served in the intensity of the 1155 cm−1 band which is mainly
assigned to the C–O stretching vibrations in glycogen [36].
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Fig. 15 The FTIR spectra of the lipid extracts of the ponatinib-treated
(dotted line) and control (continuous line) imatinib-sensitive (a) and
imatinib-resistant (b) K562 cells between 3134 and 2800 cm−1 (the spec-
tra were normalized with respect to the CH2 asymmetric stretch band
which is located at 2925 cm−1)
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Fig. 16 The FTIR spectra of the lipid extracts of the ponatinib-treated
(dotted line) and control (continuous line) imatinib-sensitive (a) and
imatinib-resistant (b) K562 cells between 1828 and 650 cm−1 (the spectra
were normalized with respect to the CH2 asymmetric stretch band which
is located at 2925 cm−1)
Table 3 FTIR band ratios of the imatinib-sensitive and imatinib-resistant K562 cells after ponatinib treatment
Unsaturation
index
Hydrocarbon
chain length
PO2/CH2 Lipids without
phosphate
Number of
acyl chains
698 cm/2924 cm
K562 cells 1.0531 1.0041 1.0734 21.9373 23.5497 1.2047
K562/IMA-3 cells 2.5863 1.2344 2.1791 0.7780 1.6955 4.2079
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Cancer cells are known to consume more carbohydrate due to
their increased energy expenditure which is known as the
Warburg effect [37]. In a similar way, MDR resistance is hy-
pothesized to require more energy for the additional tasks of
elimination of toxic compounds and drugs. Therefore, the
changes in the level of glycogen in the cancer cells upon
ponatinib application should be considered in more detail.
The decrease in CH3 asymmetric stretching vibration ab-
sorption intensity in the imatinib-resistant cells indicates a
change in the composition of the acyl chains in lipids as
shown in Fig. 2. In addition, the frequency of the CH3 asym-
metric stretch band downshifted in the both imatinib-sensitive
and imatinib-resistant K562 cells similarly indicating decreas-
ing freedom of the acyl chain in the center of the bilayer since
the CH3 asymmetric stretching mode is correlated with the
order of the deep interior of the membrane [38]. Hence, the
order in the lipid plasma membrane interior is increased in the
resistant cancer cells [39]. In addition, the intensity of the CH2
symmetric stretching band decreased in the resistant cells in-
dicating a decreasing proportion of the CH2 groups in the
resistant cells more than that in the sensitive K562 cells. Sim-
ilarly, the frequency of the bending vibration at around
1453 cm−1 upshifted in both imatinib-sensitive and imatinib-
resistant K562 cells indicating changes in the lateral packing
property of the methylene groups in the membrane lipids [40].
The DNA/protein ratio is estimated by the ratio of
1086 cm−1 and amide II bands (41). This ratio 4.35 % de-
creased for the sensitive but 1.97 % increased for the
imatinib-resistant K562 cells indicating a small decrease in
the DNA/protein ratio in the sensitive cells.
The glucose/phosphate ratio is given as the intensity ratio
of 1030 and 1086 cm−1 bands as a reliable measure of the
metabolic turnover of the cells [41, 20]. It was found to de-
crease by 4.94 % in the imatinib-sensitive and increase by
19.61 % in the imatinib-resistant K562 cells. This ratio was
found to decrease in malignant transformation when com-
pared with the normal tissues (Gazi et al.). Similarly, the
1030 and 2926 cm−1 band ratio was found to decrease by
15.22 for the imatinib-sensitive and increase by 25.46 % in
the imatinib-resistant K562 cells indicating decreasing glu-
cose and increasing phospholipid ratios for the sensitive and
vice versa for the resistant cells.
The intensity ratio of the 1121 and 1020 cm−1 bands was
observed to increase for the sensitive (6.43 %) and decrease
for the imatinib-resistant cells (25.50 %). This ratio is indica-
tive of the RNA/DNA ratio [20] and was found to increase in
the malignant cells when compared with the normal tissues.
The Amide I/Amide II ratio stays at similar levels for both
imatinib-sensitive and imatinib-resistant K562 cells upon
ponatinib treatment.
The ratio of 1740 cm−1/Amide I bands is indicative of lipid
to protein ratio of the analyzed systems [42]. This ratio indi-
cates an increase (3.75 %) in the imatinib-sensitive cells but
experiences a decrease in the imatinib-resistant cells (3.04 %)
upon ponatinib treatment.
Dovbeshko et al. [30] studied the structural alterations of
anticancer drugs such as doxorubicin on the drug-sensitive
and resistant cancer cells using surface-enhanced FTIR spec-
troscopy via the analysis of nucleic acid structure. In their
research, they found that upon treatment with doxorubicin,
the degree of disorder increased in the doxorubicin-sensitive
cancer cells; however, the same parameter was found to de-
crease in the drug-resistant cancer cells. In this research, we
followed their procedure to understand ponatinib-induced
changes in the sugar–nucleic acid backbone of the treated
K562 cells. The results of the experiments indicated that
ponatinib treatment decreases disorder in the imatinib-
sensitive K562 cells whereas the disorder in the nucleic acids
increased in the resistant K562 cells.
FTIR spectra obtained from the lipid extracts of the both
sensitive and resistant cells indicated changes upon ponatinib
application. However, the changes with the resistant cells were
more drastic when compared with that in the sensitive cells.
One of the most important changes was observed in the lipids
without phosphate indicating either a decrease in the
phosphate-containing lipids or an increase in the fatty acids
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or triglycerides and number of acyl chains indicating an in-
crease in the ester-containing lipids. In addition, important
changes were observed in the cholesterol amounts. In the re-
sistant cells, the relative ratio of cholesterol when normaliza-
tion was carried out according to 2926 cm−1 band as shown in
Figs. 10 and 11. Degree of unsaturation and hydrocarbon
chain length increased upon ponatinib treatment in the both
sensitive and resistant cells.
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